Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "overall survival" wg kryterium: Temat

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-5 z 5
    Tytuł:
    Peroxiredoxin-1 as a prognostic factor in patients with ovarian cancer
    Autorzy:
    Sieńko, J.
    Teliga-Czajkowska, J.
    Przytula, E.
    Czajkowski, K.
    Smolarczyk, R.
    Nowis, D.
    Powiązania:
    https://bibliotekanauki.pl/articles/2085041.pdf
    Data publikacji:
    2019
    Wydawca:
    Instytut Medycyny Wsi
    Tematy:
    Peroxiredoxin-1
    PRDX-1
    ovarian cancer
    overall survival
    disease free survival
    Opis:
    Introduction and objective. Peroxiredoxin-1 (PRDX-1) belongs to a family of antioxidant enzymes and has proved to be a versatile molecule regulating cell growth, differentiation and apoptosis. PRDX1-regulated signaling pathways play an important role in the progression and metastasis of human tumours, especially in breast, esophageal and lung cancers. The aim of the study was to evaluate the expression of PRDX-1 in ovarian cancer tissues, and to test the clinical value of PRDX-1 as a prognostic factor in this malignancy. Materials and method. PRDX-1 expression was assessed by automated immunohistochemistry in tumours taken from 55 patients with ovarian cancer during primary surgery. Specimen were formalin-fixed and preserved in paraffin-embedded blocks. The results were correlated with clinicopathological data. Results. A high expression of PRDX-1 was observed in 20% of cases, and was associated with worse compliance to chemotherapy protocol (P<0.002), worse response to chemotherapy (P<0.04), and higher levels of CA 125 after the 1st line treatment (P<0.004). PRDX-1 positive subjects had a significantly lower 5-year disease-free survival (9.1% vs. 42.6%, P<0.01) and a lower 5-year overall survival (9.1% vs. 56.7%; P<0.002). Multivariate analysis showed that a high expression of PRDX-1 is an independent prognostic factor of poor, overall survival (P<0.002) and a disease-free survival (P<0.01). Conclusion. Results of the study show that PRDX-1 expression in tumour tissues can be another biomarker of prognosis in patients with ovarian cancer.
    Źródło:
    Annals of Agricultural and Environmental Medicine; 2019, 26, 3; 415-419
    1232-1966
    Pojawia się w:
    Annals of Agricultural and Environmental Medicine
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Metastatic pancreatic adenocarcinoma treated with liposomal irinotecan in combination with 5-fluorouracil and leucovorin as a II line chemotherapy
    Autorzy:
    Kraj, Leszek
    Gryziak, Maciej
    Żurawińska-Grzelka, Ewa
    Woźniak, Krzysztof
    Powiązania:
    https://bibliotekanauki.pl/articles/2047205.pdf
    Data publikacji:
    2021-06-30
    Wydawca:
    Medical Education
    Tematy:
    II line chemotherapy
    liposomal irinotecan
    leucovorin
    peripheral polyneuropathy
    overall survival
    pancreatic cancer
    Opis:
    The paper presents a case of a 54-year-old man with pancreatic tumor and intraperitoneal dissemination. The patient received treatment with gemcitabine in combination with nab-paclitaxel. After 18 months, the disease progressed, therefore the line of treatment was applied in the form of liposomal irinotecan with 5-FU/LV. This therapy provided progression-free survival for 7 months. The obtained results are better than the median progression-free survival obtained in the studies. This case demonstrates that liposomal irinotecan in the treatment of stage IV disease in patients progressing after gemcitabine opens up new treatment options.
    Źródło:
    OncoReview; 2021, 11, 2; 44-47
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Survival outcome and prognostic factors in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with abiraterone acetate – real-world experience in Vietnam
    Autorzy:
    Do, Tu Anh
    Nguyen, Thai Hoa Thi
    Nguyen, Hau Xuan
    Nguyen, Loi Dinh
    Nguyen, Chu Van
    Powiązania:
    https://bibliotekanauki.pl/articles/40555372.pdf
    Data publikacji:
    2024-06-30
    Wydawca:
    Uniwersytet Rzeszowski. Wydawnictwo Uniwersytetu Rzeszowskiego
    Tematy:
    abiraterone acetate
    metastatic castration-resistant prostate cancer
    overall survival
    real-world evidence
    Opis:
    Introduction and aim. In real life, metastatic castration-resistant prostate cancer patients (mCRPC) had more complex clinical presentation than patients in the COU-AA-302 trial. This study primarily aimed to describe the overall survival of chemotherapy-naive mCRPC treated with abiraterone acetate plus prednisone (AAP). Other relevant outcomes and baseline characteristics of these patients were also evaluated. Material and methods. This retrospective, observational study collected data from chemotherapy-naive mCRPC patients treated with AAP in Vietnam. Kaplan-Meier curves were used to estimate time to treatment failure (TTF), and overall survival (OS). The impact of baseline characteristics on OS was explored using univariate and multivariate Cox proportional hazard models. Results. Data from 65 eligible patients were analyzed. The rate of PSA response was 73.8%, median PSA PFS was 10.5 months (95% CI: 7.4–13.6), median TTF was 15 months (95% CI: 11.1–18.9), and median OS was 24.9 months (95% CI: 18.9–30.9). Shorter OS was significantly associated with a higher Gleason score (≥8), shorter time from ADT start to mCRPC (<12 months), visceral metastases, and <50% PSA decline (p<0.05). Conclusion. Abiraterone acetate plus prednisone is well tolerated and effective for chemotherapy-naive mCRPC patients in clinical practice. Moreover, Gleason score, visceral metastasis, time from ADT start to mCRPC, and PSA response are the independent indicators for predicting the OS of mCRPC patients in both univariate and multivariate analyses.
    Źródło:
    European Journal of Clinical and Experimental Medicine; 2024, 22, 2; 262-269
    2544-2406
    2544-1361
    Pojawia się w:
    European Journal of Clinical and Experimental Medicine
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib-sorafenib sequence
    Autorzy:
    Kardas, Joanna
    Buraczewska, Agnieszka
    Powiązania:
    https://bibliotekanauki.pl/articles/1065215.pdf
    Data publikacji:
    2015
    Wydawca:
    Medical Education
    Tematy:
    clear cell carcinoma
    mTOR inhibitor (mTORi)
    metastatic renal cell cancer
    overall survival (OS)
    progression free survival (PFS)
    tyrosine kinase inhibitor (TKI)
    Opis:
    We presented a 39-year-old male who developed progressive cancer disease 4 years after nephrectomy due to clear cell carcinoma. He was diagnosed with locally reccurence and metastases to the liver, spleen and abdominal muscles. The patient was treated with sunitinib and then after disease progression – with sorafenib. We observed 18 months of cancer control (TKI-TKI). After second progression everolimus was administered. Third line everolimus therapy helped to achieve durable stable disease with PFS 46 months till now (May 2015). The patient remains in very good performance status with minimal toxicity from the regimen. This case illustrates a long term survival for patients with metastatic renal cell carcinoma, a malignancy with historically poor prognosis. The use of three sequential targeted therapies (TKI – TKI – mTORi) helped to achieve over 5 years or disease control, with rarely seen long-term response to third line treatment (mTORi) – where stabilization is good enough. We discussed therapeutic strategies in metastatic renal cell carcinoma according to the literature and therapeutic possibilities in Poland.
    Źródło:
    OncoReview; 2015, 5, 2; A71-75
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Life Expectancy in Patients With Stage III A Non-small Cell Lung Cancer (NSCLC) Treated With Neoadjuvant Chemoradiotherapy (NCRT), Neoadjuvant Chemotherapy (NCT), Neoadjuvant Chemotherapy + Adjuvant Radiation Therapy (NCT + Adjuvant RT)
    Przewidywana długość życia u pacjentów z niedrobnokomórkowym rakiem płuca w stadium III A (NSCLC) poddanych neoadjuwantowej chemioradioterapii (NCRT), neoadjuwantowej chemioterapii (NCT), neoadjuwantowej chemioterapii + adjuwantowej radioterapii (NCT + adjuwantowa RT)
    Autorzy:
    Maliarchuk, Katerina
    Ganul, Andrey
    Borisyuk, Bogdan
    Bororov, Leonid
    Shevchenko, Anatoly
    Sovenko, Vladimir
    Kutsenko, Lubov
    Powiązania:
    https://bibliotekanauki.pl/articles/2159225.pdf
    Data publikacji:
    2022-12-30
    Wydawca:
    Akademia Bialska Nauk Stosowanych im. Jana Pawła II w Białej Podlaskiej
    Tematy:
    neoadjuvant therapy
    pneumonectomy
    lobectomy
    non-small cell lung cancer
    overall survival
    terapia neoadjuwantowa
    pneumonektomia
    lobektomia
    niedrobnokomórkowy rak płuca
    choroby
    przeżycie całkowite
    Opis:
    Background. This work is а comparative study of survival in patients with stage III A non-small cell lung cancer (NSCLC) treated with neoadjuvant chemoradiotherapy (NCRT), neoadjuvant chemotherapy (NCT) and neoadjuvant chemotherapy and adjuvant radiation therapy (NCT + adjuvant RT). Material and methods. Three groups of 65 people were selected. The first group received NCT, the second group – NCT, and the third group – NCT + adjuvant radiation therapy. The NCRT group received radiation therapy of 30 Gy. Survival was assessed using the Kaplan and Mayer scale and according to the log rank criteria. Results. The statistical criterion for NCRT in relation to NCT was -3.51279, r=0.00044. The statistical criterion for NCRT in relation to NCT + adjuvant RT was -2.88568, r=0.00391. Less reliable dependence was observed between NCT and NCT + adjuvant RT (the statistical criterion =1.809508, p=0.070307). Conclusions. Performing NCT, NCRT or NCT + RT and the status of complete morphological response (CMR) during the revision of histological material, it is possible to predict survival for a period of up to 36 months. NCRT is the optimal method of treatment.
    Wprowadzenie. Niniejsza praca stanowi badanie porównawcze przeżycia u pacjentów z niedrobnokomórkowym rakiem płuca w stadium III A (NSCLC) w leczeniu neoadjuwantową chemioradioterapią (NCRT), neoadjuwantową chemioterapią (NCT) oraz neoadjuwantową chemioterapią i adjuwantową radioterapią (NCT + adjuwantowa RT). Materiał i metody. Wyłoniono 3 grupy po 65 osób. Pierwsza grupa otrzymała NCT, druga grupa – NCRT, a trzecia grupa – NCT + radioterapię adjuwantową. Grupa NCRT otrzymała radioterapię w dawce 30 Gy. Przeżycie oceniano za pomocą skali Kaplana i Mayera oraz według kryteriów log rank. Wyniki. Kryterium statystyczne NCRT w stosunku do NCT wyniosło -3,51279, r=0,00044. Kryterium statystyczne NCRT w stosunku do NCT + adjuwantowej RT wyniosło -2,88568, r=0,00391. Mniej wiarygodna zależność została zaobserwowana między NCT a NCT + adjuwantowa RT (kryterium statystyczne = 1,809508, p=0,070307). Wnioski. Wykonując NCT, NCRT lub NCT + RT oraz status całkowitej odpowiedzi morfologicznej (CMR) podczas rewizji materiału histolog
    Źródło:
    Health Problems of Civilization; 2022, 16, 4; 302-311
    2353-6942
    2354-0265
    Pojawia się w:
    Health Problems of Civilization
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
      Wyświetlanie 1-5 z 5

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies